Cubist Pharmaceuticals Inc., of Lexington, Mass., reported total net revenues of $211.7 million for the first quarter. Sales of Cubicin (daptomycin for injection), an antibiotic, totaled $197.4 million worldwide, with $184.7 million of that in the U.S. Sales of Entereg (alvimopan), a mu opioid receptor antagonist with gastrointestinal indications that Cubist gained in its December 2011 acquisition of Adolor Corp., totaled $9.4 million.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST